CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test
Are you or a family member experiencing symptoms of CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy? DNA Labs UAE offers a comprehensive genetic test to diagnose this condition and guide appropriate treatment and management options.
Test Details
CD59 gene hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy is a genetic disorder characterized by a deficiency or dysfunction of the CD59 protein. CD59 is a protein that helps protect red blood cells (RBCs) from destruction by the body’s immune system. In individuals with this condition, the lack or impairment of CD59 leads to increased susceptibility of RBCs to destruction, resulting in hemolytic anemia.
Hemolytic anemia is a condition where RBCs are prematurely destroyed, leading to a decrease in the number of circulating RBCs and subsequent symptoms such as fatigue, pale skin, and shortness of breath. Additionally, some individuals with this condition may also develop immune-mediated polyneuropathy, which is a disorder affecting the peripheral nerves. This can result in symptoms such as muscle weakness, numbness, and tingling in the extremities.
The NGS genetic test refers to next-generation sequencing, a high-throughput DNA sequencing technology used to analyze multiple genes simultaneously. This genetic test can be used to identify mutations or variants in the CD59 gene, helping to confirm a diagnosis of CD59 gene hemolytic anemia and guide appropriate treatment and management options.
It is important to note that this genetic test is typically performed by a healthcare professional, such as a geneticist or genetic counselor, and requires a blood or saliva sample from the individual being tested. The results of the test can provide valuable information about the specific genetic variants present in the CD59 gene and aid in understanding the underlying cause of the condition.
Test Components
Components: CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Osteology Dermatology Immunology Disorders
Pre Test Information
Prior to undergoing the CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test, it is important to provide a clinical history of the patient. Additionally, a genetic counseling session may be necessary to draw a pedigree chart of family members affected by CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy NGS Genetic DNA Test gene CD59.
Conclusion
If you or a loved one are experiencing symptoms of CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy, it is crucial to undergo the CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test offered by DNA Labs UAE. This comprehensive genetic test can provide valuable insights into the underlying cause of the condition and guide appropriate treatment and management options. Don’t wait, schedule your test today!
| Test Name | CD59 Gene Hemolytic anemia CD59-mediated with or without immune-mediated polyneuropathy Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Osteology Dermatology Immunology Disorders |
| Doctor | Dermatologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for CD59 Gene Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CD59 Gene Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy NGS Genetic DNA Test gene CD59 |
| Test Details |
CD59 gene hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy is a genetic disorder characterized by a deficiency or dysfunction of the CD59 protein. CD59 is a protein that helps protect red blood cells (RBCs) from destruction by the body’s immune system. In individuals with this condition, the lack or impairment of CD59 leads to increased susceptibility of RBCs to destruction, resulting in hemolytic anemia. Hemolytic anemia is a condition where RBCs are prematurely destroyed, leading to a decrease in the number of circulating RBCs and subsequent symptoms such as fatigue, pale skin, and shortness of breath. Additionally, some individuals with this condition may also develop immune-mediated polyneuropathy, which is a disorder affecting the peripheral nerves. This can result in symptoms such as muscle weakness, numbness, and tingling in the extremities. The NGS genetic test refers to next-generation sequencing, a high-throughput DNA sequencing technology used to analyze multiple genes simultaneously. This genetic test can be used to identify mutations or variants in the CD59 gene, helping to confirm a diagnosis of CD59 gene hemolytic anemia and guide appropriate treatment and management options. It is important to note that this genetic test is typically performed by a healthcare professional, such as a geneticist or genetic counselor, and requires a blood or saliva sample from the individual being tested. The results of the test can provide valuable information about the specific genetic variants present in the CD59 gene and aid in understanding the underlying cause of the condition. |
